<p>REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clo
<ul><li>I wish that September rate hike was the last one</li><li>But cannot rule out further moves</li><li>Only via the March forecast next year can we confirm the
Leave a Comment